• Martin Shkreli’s appearance at UC Davis was scrapped due to student protests, but he may get a better reception at Harvard and UMass Boston, where he’s scheduled to make appearances this week. Shkreli’s college tour is rolling out ahead of his scheduled trial this summer, where he will face fraud charges. The infamous biotech exec and former Twitter troll — he was banned recently — achieved considerable notoriety when his company, Turing, acquired an old generic and raised the price 5000%.
• The UK’s Vernalis (LSE: VER) has picked up a $3 million milestone payment from Corvus Pharmaceuticals.
• The Royal College of Surgeons in Ireland struck a deal with Almac Discovery to collaborate on a project to target drug resistant tumor cells responsible for metastsasis.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription